Universal sterile connectors simplify single-use systems integration
Colder&s new genderless AseptiQuik G Connectors make single-use sterile connections faster, easier and safer?even in non-sterile conditions. Universal mating simplifies systems integration, increases process flexibility and minimizes operator error.
Universal sterile connectors simplify single-use systems integration
New genderless AseptiQuik® G Connectors from Colder Products Company make single-use sterile connections faster, easier and safer than ever before—even in non-sterile conditions.
The genderless design eliminates separate male and female components, allowing any G series connectors to mate together. This universal “G” mating simplifies systems integration and increases process flexibility for transferring valuable media.
The unique design of AseptiQuik G connectors minimizes the risk of operator error, reduces complexity, labor and inventory requirements. The new G series is available in a full range of interchangeable 1/4” to 3/4” flow solutions, in both gamma and high-temperature versions. Terminations include 1/4” hose barb, 1/2” hose barb, 3/4” hose barb and 3/4” sanitary.
The AseptiQuik family of connectors—in a full range of 1/8” to 1” flow configurations—provides unequalled ease of use and robust construction for reliable, repeatable performance without burdensome assembly aids, clamps or tube welding. AseptiQuik connectors are ideal for single-use bag and tubing assemblies, bioreactors, mixers, sampling and filling applications. For applications where reliability and sterility are a must, Connect with Colder.
See how easy connections are with AseptiQuik® G —click here for video.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
